Impact of the coronavirus 2019 (COVID-19) pandemic on anxiety diagnosis in general practices in Germany.
Impact of the coronavirus 2019 (COVID-19) pandemic on anxiety diagnosis in general practices in Germany.
复制标题
DOI：
10.1016/j.jpsychires.2020.11.029
复制
发表时间：
2021-11
影响因子：
4.8
通讯作者：
Kostev K
中科院分区：
文献类型：
--
作者：
Jacob L;Smith L;Koyanagi A;Oh H;Tanislav C;Shin JI;Konrad M;Kostev K
人们对2019冠状病毒病（COVID-19）大流行对焦虑症诊断的影响知之甚少。因此，本研究的目的是比较2019年1月至6月和2020年1月至6月期间德国被诊断为焦虑症的成年人数量和新诊断为焦虑症的成年人数量，并确定这些患者在社会人口学特征、处方和合并症方面的潜在差异。该研究包括在2019年1月至6月和2020年1月至6月期间在德国1140个全科诊所中至少接受过一次咨询的患者。社会人口学特征包括年龄和性别，同时有三个药物家族和九种常见合并症可供分析。与2019年相比，2020年焦虑障碍患者人数有所增加（1月：+4%，p = 0.643； 2月：+4%，p = 0.825； 3月：+34%，p < 0.001； 4月：+8%，p = 0.542； 5月：+2%，p = 0.382； 6月：+19%，p = 0.043； 3 - 6月：+19%，p < 0.001）。在2020年3月至6月和2019年3月至6月期间，新诊断为焦虑症的患者数量也有所增加（11,502对9506；+21%，p值<0.001）。与2019年相比，2020年新诊断为焦虑症的患者使用抗抑郁药、抗焦虑药和草药镇静剂的频率较低（30.4%比35.6%，p值<0.001）。最后，COPD（9.4%比7.9%，p值<0.001）和哮喘（11.3%比9.7%，p值<0.001）在2020年比2019年更常见。综合这些发现，迫切需要采取公共卫生措施，以减轻COVID-19大流行对焦虑症的负面影响。
Little is known about the effects of the coronavirus disease-2019 (COVID-19) pandemic on the diagnosis of anxiety disorder. Therefore, the goal of this study was to compare the number of adults with a diagnosis of anxiety disorder and the number of adults newly diagnosed with anxiety disorder in Germany between January–June 2019 and January–June 2020, and to identify potential differences in terms of sociodemographic characteristics, prescriptions and comorbidities between these patients. The study included patients with at least one consultation in one of 1140 general practices in Germany in January–June 2019 and January–June 2020. Sociodemographic characteristics included age and sex, while there were three families of drugs and nine common comorbidities available for the analysis. An increase in the number of patients with anxiety disorder was observed in 2020 compared with 2019 (January: +4%, p = 0.643; February: +4%, p = 0.825; March: +34%, p < 0.001; April: +8%, p = 0.542; May: +2%, p = 0.382; June: +19%, p = 0.043; and March–June: + 19%, p < 0.001). There was also an increase in the number of patients newly diagnosed with anxiety disorder between March–June 2020 and March–June 2019 (11,502 versus 9506; +21%, p-value<0.001). Antidepressants, anxiolytics and herbal sedatives were less frequently prescribed in patients newly diagnosed with anxiety disorder in 2020 than in 2019 (30.4% versus 35.6%, p-value<0.001). Finally, COPD (9.4% versus 7.9%, p-value<0.001) and asthma (11.3% versus 9.7%, p-value<0.001) were more frequent in 2020 than in 2019. Taken these findings together, public health measures are urgently needed to mitigate the negative impact of the COVID-19 pandemic on anxiety disorder.
登录
查看更多内容
影响因子：
8.1
作者：
Jalloh MF;Li W;Bunnell RE;Ethier KA;O'Leary A;Hageman KM;Sengeh P;Jalloh MB;Morgan O;Hersey S;Marston BJ;Dafae F;Redd JT
通讯作者：
Redd JT
影响因子：
11.3
作者：
Cao, Wenjun;Fang, Ziwei;Zheng, Jianzhong
通讯作者：
Zheng, Jianzhong
影响因子：
5.2
作者：
Bu, F.;Steptoe, A.;Fancourt, D.
通讯作者：
Fancourt, D.
影响因子：
56.3
作者：
Boehmer, Merle M.;Buchholz, Udo;Zapf, Andreas
通讯作者：
Zapf, Andreas
DOI：
10.1016/j.ijantimicag.2020.106024
发表时间：
2020-08-01
影响因子：
10.8
作者：
Lai, Chih-Cheng;Ko, Wen-Chien;Hsueh, Po-Ren
通讯作者：
Hsueh, Po-Ren